Literature DB >> 28405755

[Sarcoidosis : Renal manifestations].

C Löffler1, R Bergner2.   

Abstract

Renal involvement in sarcoidosis is much more common than generally assumed from old epidemiological studies and is often only detected when actively searched for. Many patients with renal sarcoidosis present with no or only few symptoms. The diagnostic work-up of sarcoidosis should always include a possible renal involvement. In cases of impaired renal function, proteinuria or a pathological urine sediment, a renal biopsy specimen should be obtained to assess the type, severity and prognosis of the kidney disease. Treatment is primarily based on the use of corticosteroids. Steroid-sparing agents, such as disease-modifying antirheumatic drugs and infliximab can be applied; however, the evidence for efficacy of these therapies is mostly based on case series and expert opinions. Discontinuation of immunosuppression therapy bears a high risk of relapse.

Entities:  

Keywords:  Corticosteroids; Glomerulonephritis; Granulomatous interstitial nephritis; Nephrocalcinosis; Renal manifestation

Mesh:

Substances:

Year:  2017        PMID: 28405755     DOI: 10.1007/s00393-017-0301-9

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  39 in total

Review 1.  Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis.

Authors:  M A Judson; R P Baughman; A S Teirstein; M L Terrin; H Yeager
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  1999-03       Impact factor: 0.670

2.  HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis.

Authors:  M Berlin; A Fogdell-Hahn; O Olerup; A Eklund; J Grunewald
Journal:  Am J Respir Crit Care Med       Date:  1997-11       Impact factor: 21.405

3.  Renal sarcoidosis: epidemiological and follow-up data in a cohort of 27 patients.

Authors:  C Löffler; Uta Löffler; Anika Tuleweit; R Waldherr; M Uppenkamp; R Bergner
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2015-01-05       Impact factor: 0.670

Review 4.  Genotyping increases the yield of angiotensin-converting enzyme in sarcoidosis--a systematic review.

Authors:  Andreas Fløe; Hans Jürgen Hoffmann; Peter H Nissen; Holger Jon Møller; Ole Hilberg
Journal:  Dan Med J       Date:  2014-05       Impact factor: 1.240

Review 5.  Treatment of renal sarcoidosis: is there a guideline? Overview of the different treatment options.

Authors:  Ingeborg Hilderson; Steven Van Laecke; Anne Wauters; Jan Donck
Journal:  Nephrol Dial Transplant       Date:  2013-11-13       Impact factor: 5.992

6.  Sarcoid granulomatous nephritis with isolated and reversible renal failure. A case report.

Authors:  L Allegri; G Olivetti; S David; G M Concari; G Dascola; G Savazzi
Journal:  Nephron       Date:  1980       Impact factor: 2.847

7.  Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

Authors:  Thomas Rauen; Frank Eitner; Christina Fitzner; Claudia Sommerer; Martin Zeier; Britta Otte; Ulf Panzer; Harm Peters; Urs Benck; Peter R Mertens; Uwe Kuhlmann; Oliver Witzke; Oliver Gross; Volker Vielhauer; Johannes F E Mann; Ralf-Dieter Hilgers; Jürgen Floege
Journal:  N Engl J Med       Date:  2015-12-03       Impact factor: 91.245

8.  Interstitial and glomerular renal involvement in sarcoidosis.

Authors:  Hayet Kaaroud; Lilia Ben Fatma; Soumaya Beji; Ahmed Jeribi; H Ben Maiz; Fatma Ben Moussa; Rym Goucha; Sami Turki; Adel Kheder
Journal:  Saudi J Kidney Dis Transpl       Date:  2008-01

9.  Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial.

Authors:  M A Judson; R P Baughman; U Costabel; S Flavin; K H Lo; M S Kavuru; M Drent
Journal:  Eur Respir J       Date:  2008-02-06       Impact factor: 16.671

10.  Sarcoidosis in native and transplanted kidneys: incidence, pathologic findings, and clinical course.

Authors:  Serena M Bagnasco; Srinivas Gottipati; Edward Kraus; Nada Alachkar; Robert A Montgomery; Lorraine C Racusen; Lois J Arend
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.